Cox enzyme inhibitor, celecoxib, reduces steatosis and liver lipogenesis in high-fat fed mice

Jamille Fernandes Lula; Bruna Mara Aparecida de Carvalho Mesquita; Leandro de Freitas Teles; Sérgio Henrique Sousa Santos; Alfredo Maurício Batista de Paula; André Luiz Sena Guimaraes; Erivelton Pereira dos Santos; Deborah de Farias Lelis; Luís Paulo Oliveira; Lucyana Conceição Farias; Igor Viana Brandi; Karla Nayara de Oliveira Santana

Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/42592

Full metadata record

DC Field	Value	Language
dc.creator	Jamille Fernandes Lula	pt_BR
dc.creator	Bruna Mara Aparecida de Carvalho Mesquita	pt_BR
dc.creator	Leandro de Freitas Teles	pt_BR
dc.creator	Sérgio Henrique Sousa Santos	pt_BR
dc.creator	Alfredo Maurício Batista de Paula	pt_BR
dc.creator	André Luiz Sena Guimaraes	pt_BR
dc.creator	Erivelton Pereira dos Santos	pt_BR
dc.creator	Deborah de Farias Lelis	pt_BR
dc.creator	Luís Paulo Oliveira	pt_BR
dc.creator	Lucyana Conceição Farias	pt_BR
dc.creator	Igor Viana Brandi	pt_BR
dc.creator	Karla Nayara de Oliveira Santana	pt_BR
dc.date.accessioned	2022-06-22T12:43:09Z	-
dc.date.available	2022-06-22T12:43:09Z	-
dc.date.issued	2017	-
dc.citation.volume	14	pt_BR
dc.citation.issue	2	pt_BR
dc.citation.spage	114	pt_BR
dc.citation.epage	119	pt_BR
dc.identifier.doi	http://doi.org/10.2174/1573408014666171220152537	pt_BR
dc.identifier.issn	1875-6662	pt_BR
dc.identifier.uri	http://hdl.handle.net/1843/42592	-
dc.description.resumo	Background: Obesity is an important risk factor for nonalcoholic fatty liver disease which varies from hepatic steatosis to liver cirrhosis. Interventions in weight and metabolic control are important in reducing steatosis risk. Aims: The aim of the present study was to investigate the role of celecoxib in hepatic triacylglycerol deposition in non-alcoholic fatty liver disease exploring the signaling involved in obese mice lipogenesis. Methods: Males FVB/N mice were allocated into three groups and were fed with experimental diets: standard, a high-fat diet or a high-fat diet along with Cox-2 inhibitor treatment (Celecoxib; 100mg/kg of body weight). The body weight, food intake, blood parameters and liver histology were analyzed. Expression of liver lipogenesis-related genes (ACC, PPAR-γ, FAS, SREBP-1c) was evaluated by quantitative real-time PCR. Results: The main findings showed that celecoxib treatment resulted in body weight loss in obese animals, reduced food consumption and decreased triglycerides. ACC, FAS and SREBP1-c mRNA expression was significantly suppressed in HFD+ICOX-2 fed mice. Conclusion: Celecoxib improved lipid metabolism and decreased fat deposition in the liver of obese mice by reducing lipogenesis, which may be a promising therapeutic target for liver disorders, obesity and its comorbidities.	pt_BR
dc.language	eng	pt_BR
dc.publisher	Universidade Federal de Minas Gerais	pt_BR
dc.publisher.country	Brasil	pt_BR
dc.publisher.department	ICA - INSTITUTO DE CIÊNCIAS AGRÁRIAS	pt_BR
dc.publisher.initials	UFMG	pt_BR
dc.relation.ispartof	Current Enzyme Inhibition	pt_BR
dc.rights	Acesso Restrito	pt_BR
dc.subject.other	Analgésicos	pt_BR
dc.subject.other	Enzimas	pt_BR
dc.subject.other	Inibidores enzimáticos	pt_BR
dc.subject.other	Agentes anti-inflamatórios	pt_BR
dc.subject.other	Fígado gorduroso	pt_BR
dc.subject.other	Obesidade	pt_BR
dc.title	Cox enzyme inhibitor, celecoxib, reduces steatosis and liver lipogenesis in high-fat fed mice	pt_BR
dc.type	Artigo de Periódico	pt_BR
dc.url.externa	http://www.eurekaselect.com/article/87479	pt_BR
dc.identifier.orcid	https://orcid.org/ 0000-0001-8980-8599	pt_BR
dc.identifier.orcid	https://orcid.org/0000-0001-6714-7996	pt_BR
Appears in Collections:	Artigo de Periódico

Files in This Item:

There are no files associated with this item.

Show simple item record